别名 Malignant soft tissue tumor of skeletal muscle differentiation、Malignant soft tissue tumour of skeletal muscle differentiation、RHABDOMYOSARCOMA + [24] |
简介 A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) |
靶点 |
作用机制 IGF-1R拮抗剂 |
原研机构 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2020-01-21 |
靶点 |
作用机制 SMO拮抗剂 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2015-07-24 |
靶点 |
作用机制 PD-1抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2014-07-04 |
开始日期2026-01-01 |
申办/合作机构 |
开始日期2024-10-01 |
申办/合作机构 |
开始日期2024-07-03 |
申办/合作机构 |